Chitosan-based nanoparticles for topical genetic immunization

Numerous studies have reported the prophylactic and therapeutic use of genetic vaccines for combating a variety of infectious diseases in animal models. Recent human clinical studies with the gene gun have validated the concept of direct targeting of dendritic cells (Langerhan’s cells) in the viable epidermis of the skin. However, it is unclear whether the gene gun technology or other needle-free devices will become commercially viable. The objective of our studies was to investigate the topical application of chitosan-based nanoparticles containing plasmid DNA (pDNA) as a potential approach to genetic immunization. Two types of nanoparticles were investigated: (i) pDNA-condensed chitosan nanoparticles, and (ii) pDNA-coated on pre-formed cationic chitosan/carboxymethylcellulose (CMC) nanoparticles. These studies showed that both chitosan and a chitosan oligomer can complex CMC to form stable cationic nanoparticles for subsequent pDNA coating. Selected pDNA-coated nanoparticles (with pDNA up to 400 μg/ml) were stable to challenge with serum. Several different chitosan-based nanoparticles containing pDNA resulted in both detectable and quantifiable levels of luciferase expression in mouse skin 24 h after topical application, and significant antigen-specific IgG titer to expressed β-galactosidase at 28 days.